Utah Medical Products, Inc. UTMD

FY2025 · ended Dec 31, 2025 · Revenue $38.52M, -5.8% YoY · Filed Mar 27, 2026

Utah Medical Products, Inc. (UTMD) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $38.5 million and net income of $11.3 million. Free cash flow was $14.3 million. As of Jun 30, 2026 it held $87.5 million in cash and investments and $195,000 in total debt.

Revenue (TTM)
$36.11M
-7.0% vs year-ago TTM
Net income (TTM)
$10.49M
-16.5% vs year-ago TTM
Operating cash flow (TTM)
$11.85M
-16.2% vs year-ago TTM
Free cash flow (TTM)
$11.45M
-17.0% vs year-ago TTM
EPS (TTM)
$3.28
-12.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
3.19M
-2.9% vs prior year
Net cash
$87.33M
as of Jun 30, 2026
Operating margin
28.4%
FY 2026

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
UTMD (Nasdaq)
Fiscal year ends
December 31
Incorporated in
UT
Headquarters
Midvale, UT
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
706698

Other Surgical & Medical Instruments & Apparatus companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

Line
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
Revenue
$38.5M
$40.9M
$50.2M
$52.3M
$49.1M
Operating income
$11.4M
$13.6M
$16.8M
$19.8M
$18.9M
Net income
$11.3M
$13.9M
$16.6M
$16.5M
$14.8M
Diluted EPS
$3.48
$3.96
$4.57
$4.52
$4.04
Operating cash flow
$14.7M
$14.8M
$22.3M
$21.1M
$21.2M
Free cash flow
$14.3M
$14.6M
$21.6M
$20.3M
$20.7M
Total assets
$122.5M
$122.5M
$135.5M
$123.9M
$115.6M
Total liabilities
$3.3M
$5.1M
$7.1M
$9.6M
$8.5M
Stockholders' equity
$119.3M
$117.4M
$128.3M
$114.3M
$107.1M
Cash and investments
$85.8M
$83.0M
$92.9M
$75.1M
$61.0M
Total debt
$286,000
$338,000
$342,000
$395,000
$449,000

Recent SEC filings

Recent SEC filings
Form Description Filed Period
8-K Current report
Other events
Nov 3, 2026 Nov 3, 2026
8-K Current report
Results of operations
Oct 22, 2026 Oct 22, 2026
8-K Current report
Regulation FD disclosure
Aug 31, 2026 Aug 31, 2026
10-Q Quarterly report Aug 12, 2026 Jun 30, 2026
8-K Current report
Results of operations
Jul 23, 2026 Jul 23, 2026
10-Q Quarterly report May 12, 2026 Mar 31, 2026

Source: SEC EDGAR filings. This is company-reported data, not investment advice.